Fisher & Paykel Healthcare Corp. has launched the F&P my820 respiratory humidifier in the United States.
The F&P my820 “provides heated humidification during the delivery of invasive ventilation, noninvasive ventilation, and humidified high-flow therapies for adult and pediatric patients,” the company said in an Aug. 1 news announcement.
The system, designed to be used in home environments, “automatically adapts to environmental temperature changes using a built-in sensor” to enable the F&P my820 to adjust to fluctuating home temperatures. “This sensor works to mitigate circuit condensate while also reducing device-wire clutter and providing patients with a simplified set-up process,” Fisher & Paykel added.
The F&P my820 is now also available in Australasia, Europe and Canada. The company intends to release the system in additional markets as it receives regulatory clearances.
“The F&P my820 is the result of years of dedicated investment in new technologies that improve care and outcomes for patients in their homes,” said Andrew Somervell, VP – products and technology. “It provides peace of mind that adults and children can continue to receive high-quality care after they leave the hospital.”
Fisher & Paykel noted in its F&P my820 brochure that the benefits of heated humidification include “maintaining secretion clearance in patients with a bypassed airway, as well as supporting comfort and tolerance to NIV [noninvasive ventilation].”
The heated F&P my820 inspiratory breathing tubes and the manual fill chambers can be used by a single patient for up to 14 days. The system has four humidity settings that can be selected by the user or caregiver. The F&P my820’s alarm systems will alert users and caregivers when the water chamber is empty or the heater wire needs to be checked.
